Adverse Event Report
Unit 603 and 604, 6th Floor, Ryan Vanak Building, No. 18, West Side of Sheikh Baha'i Square, Tehran, Iran
(+98) 21 45395
PerkinRA® contains the active substance which is named Anakinra (an immunosuppressive agent). Cytokines are proteins synthesized in body and coordinate inter-cellular communication, and contribute to controlling cell activities.
In Rheumatoid Arthritis (RA), Cryopyrin- Associated Periodic Syndrome (CAPS) and in Still’s Disease, your body produces large amounts of cytokine, called Interleukin-1, which causes harmful effects such as inﬂammation and development of disease symptoms. Your body generally produces proteins to suppress the harmful impacts of Interleukin1-; Anakinra, the active substance of PerkinRA®, does the same work as these suppressing proteins. Anakinra has been manufactured by DNA technology using E.coli microorganism.
PerkinRA® is prescribed for the following diseases:
• Cryopyrin-associated periodic syndromes (CAPS)
• Neonatal-Onset Multisystem Inﬂammatory Disease (NOMID), also known as Chronic Infantile Neurologic Cutaneous and Articular Syndrome (CINCA).
• Muckle - Wells Syndrome (MWS)
• Familial Cold auto- Inﬂammatory Syndrome (FCAS)
What you need to know before you use PerkinRA®?
Do not use PerkinRA® in following cases:
• If you are allergic to anakinra
• If you are allergic to other medicines manufactured by DNA technology using E.coli microorganism.
• If the blood test shows you are suffering from neutropenia disease (reduction in white blood cells).
Does PerkinRA® have any drug interaction?
Mechanism of action of PerkinRA®:
PerkinRA® blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. IL-1 has a broad range of activities including cartilage degradation by its induction of the rapid loss of proteoglycans, as well as stimulation of bone resorption. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from RA patients are not sufficient to compete with the elevated amount of locally produced IL-1.
Dosage form: prefilled syringe 100 mg/0.67 ml
Color: colourless-to-white solutions
Storage: 2° to 8°C (36° to 46°F)
For adverse event report and contact with patient support unit
Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial
Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial
Arta Pharmed Company, located in Tehran, Iran, is one of the new pharmaceutical companies that focuses on clinical studies, sales, marketing, market development, market access and scientific activities. This company, which was established in 2018, currently cooperates with more than 15 companies in various fields.
Unit 603 and 604, 6th Floor, Rayan Vanak Building, No. 18, West Side of Sheikh Bahaei Square, Tehran, Iran
Copyright © 2022 Arta Pharmed
Developed by "Arta Pharmed-Technical Dep."